An Open‐Label, Single‐Arm, Phase <scp>II</scp> Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line <scp>PD</scp> ‐(L)1 Inhibitor

Authors

Guangyuan Lou (ORCID: https://orcid.org/0000-0003-0551-3422)
Lin Chen (ORCID: https://orcid.org/0009-0005-1741-0975)
Ying Jin (ORCID: https://orcid.org/0000-0002-6829-7926)
Xinmin Yu
Wei Hong (ORCID: https://orcid.org/0000-0002-8359-9703)
Lishu Lou
Qiong He (ORCID: https://orcid.org/0009-0002-5075-7856)
Jun Zhao (ORCID: https://orcid.org/0000-0003-1464-7158)
Lan Shao (ORCID: https://orcid.org/0000-0002-0770-0953)
Xun Shi
Cuiping Gu

Institutions

Chinese Academy of Sciences (CN)
Zhejiang Cancer Hospital (CN)
Hangzhou Cancer Hospital (CN)

Publication Details

Journal: Cancer Medicine
Published: 2025-09-01
DOI: https://doi.org/10.1002/cam4.71191
Citations: 3
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 3.14

Funders

National Natural Science Foundation of China
Medical and Health Research Project of Zhejiang Province
Natural Science Foundation of Zhejiang Province

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor

Guangyuan Lou, Lin Chen, Ying Jin, Xinmin Yu et al.

Sep 1, 2025

3 citations

Cancer Medicine

Cancer Immunotherapy and Biomarkers

3.14

article

An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor

Guangyuan Lou, Lin Chen, Ying Jin, Xinmin Yu, Wei Hong, Lishu Lou, Qiong He, Jun Zhao, Lan Shao, Xun Shi, Cuiping Gu

September 1, 2025article en

3 citations

Abstract

No abstract available for this paper.

Cancer MedicineVol. 14(17)

Chinese Academy of Sciences (CN), Zhejiang Cancer Hospital (CN), Hangzhou Cancer Hospital (CN)

National Natural Science Foundation of China, Medical and Health Research Project of Zhejiang Province, Natural Science Foundation of Zhejiang Province

Openalex Percentile: Top 7%

Cancer Immunotherapy and Biomarkers

3.14

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

An Open‐Label, Single‐Arm, Phase <scp>II</scp> Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line <scp>PD</scp> ‐(L)1 Inhibitor — Guangyuan Lou, Lin Chen, et al. · Cancer Medicine (2025) | TGRS Research Map | TGRS